Company intelligence / Profile preview
Osmotica Pharmaceuticals
Marietta, Georgia, United Statesosmotica.com ↗
- Ownership
- Private
- Employees
- ~110
- Development stage
- Other
01
Overview
Prior to its acquisition by Alora Pharmaceuticals in August 2021, Osmotica had a robust commercial portfolio including FDA-approved drugs such as Upneeq® and was advancing late-stage candidates like arbaclofen ER for MS spasticity. The company was also known for its proprietary extended-release and osmotic drug delivery technologies.
- Therapeutic areas
- NephrologyOphthalmologyNeurologyWomen's Health
- Modalities
- Small moleculeExtended release formulationsDrug delivery technology
- Industry
- Biotech
02
Drug pipeline
3 assets2 more assets in the full pipeline.
Request access →Beyond the preview
Go deeper on Osmotica Pharmaceuticals.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Osmotica Pharmaceuticals.